Cure8 research brief
Individual factors like CYP2C9 genotype and liver impairment can raise etrasimod levels. The study’s model-based dose suggestions could help personalize dosing to reduce risk of excess exposure.
Patients on etrasimod, clinicians treating ulcerative colitis/IBD, pharmacologists, and researchers interested in individualized dosing.
This PubMed abstract reports a physiologically based pharmacokinetic (PBPK) modelling study of etrasimod — an oral S1P receptor modulator approved for moderate-to-severe ulcerative colitis — focusing on effects of CYP2C9 genetic variants and hepatic impairment in Chinese populations.
The researchers validated a PBPK model against clinical and in vitro data, then used it to predict how CYP2C9 poor metabolizer status and varying degrees of liver impairment change etrasimod exposure. The model predicted increased drug exposure when either factor was present and the largest increase when both co-occurred.
Based on exposure-matching, the study proposes model-informed dose reductions: generally to 1.5 mg once daily for many affected subgroups and to 1 mg once daily for patients who are CYP2C9 poor metabolizers with Child–Pugh C hepatic impairment. This is a modelling/PK prediction study, not a prospective clinical trial testing those reduced doses.
This is a modelling study reported as an abstract; proposed dose adjustments are predictions and not clinical trial results. Confirm changes against clinical guidelines or product labeling.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with ulcerative colitis taking etrasimod may have higher drug levels if they have certain CYP2C9 genotypes or significant liver impairment; dose adjustments could be needed to avoid increased exposure.
This abstract reports that etrasimod improved multiple measures of disease activity versus placebo in patients who had inadequate response to conventional UC therapies, indicating it may be a useful first-line advanced...
S1P receptor modulators are an emerging oral class of advanced therapy for moderate-to-severe ulcerative colitis; a systematic review that pools multiple RCTs helps clarify how effective and safe the class appears to be...
